{
  "id": 19793497,
  "title": "KeyBanc cuts NeuroPace stock price target on lowered estimates",
  "url": "https://urgent.news/2026/11/13/keybanc-cuts-neuropace-stock-price-target-on-lowered-estimates",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T10:36:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/keybanc-cuts-neuropace-stock-price-target-on-lowered-estimates-93CH-5024715"
  },
  "original_language": "en",
  "account": "KeyBanc has revised its price target for NeuroPace Inc (NASDAQ:NPCE) shares downward to $14.00 from the previous $18.00. The investment firm maintained an Overweight rating on the stock, citing a material setback to the company's growth trajectory in the third quarter of 2026. KeyBanc analyst Brett Fishbin attributed the revenue shortfall to multiple factors, which prompted the downgrade of the estimates. NeuroPace forecasted a modest growth of 5% for its RNS product in the fourth quarter and expects a recovery of around 15% growth in 2027. The company's shares are trading at approximately $8.00, significantly below the current price of $12.02 and nearing the 52-week low of $11.90. NeuroPace's stock has declined by 22% year-to-date, as reported by InvestingPro data, which indicates that analyst price targets range from $18 to $22. Despite the guidance reduction, KeyBanc remains optimistic about the potential of upcoming clinical catalysts for the medical device company, considering the risk-reward profile as more favorable than unfavorable at the present trading levels.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}